Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
ARQT Transcript
Arcutis Biotherapeutics, Inc. (ARQT) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call summary indicates a positive sentiment due to a 20% revenue increase and a 10% improvement in net loss, suggesting strong product sales and cost efficiency. Although cash reserves decreased, this was due to strategic investments. The lack of explicit or implied risks and the absence of concerning Q&A responses further support a positive outlook. Given the small-cap status, the stock price is likely to react positively, falling within the 2% to 8% range.
Arcutis Biotherapeutics, Inc. (ARQT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Neutral9-9
Arcutis Biotherapeutics, Inc. (ARQT) Presents At Citi's Biopharma Back To School Conference Transcript
Neutral9-3
Arcutis Biotherapeutics, Inc. (ARQT) Q2 2025 Earnings Call Transcript
Positive8-7
The earnings call summary and Q&A provide a positive outlook. The company reported strong financial metrics, including a 28% QoQ sales growth and positive cash flow. ZORYVE's market expansion and upcoming approvals suggest future revenue growth. The Q&A highlighted optimism for pediatric opportunities and intellectual property strength. Despite some uncertainties in Medicare Part D coverage and IST study timelines, the overall sentiment remains positive with stable gross-to-net dynamics and strategic partnerships. Given the company's small-cap status, these factors are likely to result in a 2% to 8% stock price increase.
ARQT Slides
ARQT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
